Labcorp Holdings Inc. (LH) stock
LHNYSEServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/3018% above fair value
$372.46+1.98 (+0.53%)
Close on Nov 16, 2026Market cap $30.24BP/E 30.6Yield 0.77%
Labcorp EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Labcorp's EPS for the twelve months ending Sep 30, 2026 was $12.19, up 19.6% year over year. For fiscal 2025 it was $10.46, up 18.3% from the year before. Over ten years it grew 9.2% a year on average. The highest annual figure on record is $24.39 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.46 | +18.3% |
| FY2024 | Dec 31, 2024 | $8.84 | +85.3% |
| FY2023 | Dec 31, 2023 | $4.77 | -65.9% |
| FY2022 | Dec 31, 2022 | $13.97 | -42.7% |
| FY2021 | Dec 31, 2021 | $24.39 | +53.6% |
| FY2020 | Dec 31, 2020 | $15.88 | +90.2% |
| FY2019 | Dec 31, 2019 | $8.35 | -3.0% |
| FY2018 | Dec 31, 2018 | $8.61 | -27.1% |
| FY2017 | Dec 31, 2017 | $11.81 | +73.2% |
| FY2016 | Dec 31, 2016 | $6.82 | +56.8% |
| FY2015 | Dec 31, 2015 | $4.35 | -26.4% |
| FY2014 | Dec 31, 2014 | $5.91 | -5.4% |
| FY2013 | Dec 31, 2013 | $6.25 | +4.3% |
| FY2012 | Dec 31, 2012 | $5.99 | +17.2% |
| FY2011 | Dec 31, 2011 | $5.11 | -3.4% |
| FY2010 | Dec 31, 2010 | $5.29 | +6.2% |
| FY2009 | Dec 31, 2009 | $4.98 | +19.7% |
| FY2008 | Dec 31, 2008 | $4.16 | +5.9% |
| FY2007 | Dec 31, 2007 | $3.93 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.22 | +3.2% |
| Q2 FY2026 | Jun 30, 2026 | $3.64 | +28.2% |
| Q1 FY2026 | Mar 31, 2026 | $3.35 | +32.9% |
| Q4 FY2025 | Dec 31, 2025 | $1.98 | +15.8% |
| Q3 FY2025 | Sep 30, 2025 | $3.12 | +56.0% |
| Q2 FY2025 | Jun 30, 2025 | $2.84 | +16.9% |
| Q1 FY2025 | Mar 31, 2025 | $2.52 | -6.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.71 | – |
| Q3 FY2024 | Sep 30, 2024 | $2.00 | -5.2% |
| Q2 FY2024 | Jun 30, 2024 | $2.43 | +14.6% |
| Q1 FY2024 | Mar 31, 2024 | $2.69 | +12.6% |
| Q4 FY2023 | Dec 31, 2023 | -$1.50 | -142.6% |
| Q3 FY2023 | Sep 30, 2023 | $2.11 | -45.9% |
| Q2 FY2023 | Jun 30, 2023 | $2.12 | -45.2% |
| Q1 FY2023 | Mar 31, 2023 | $2.39 | -54.3% |
| Q4 FY2022 | Dec 31, 2022 | $3.52 | -38.7% |
| Q3 FY2022 | Sep 30, 2022 | $3.90 | -35.5% |
| Q2 FY2022 | Jun 30, 2022 | $3.87 | -18.7% |
| Q1 FY2022 | Mar 31, 2022 | $5.23 | -33.1% |
| Q4 FY2021 | Dec 31, 2021 | $5.74 | -39.9% |
| Q3 FY2021 | Sep 30, 2021 | $6.05 | -15.6% |
| Q2 FY2021 | Jun 30, 2021 | $4.76 | +100.8% |
| Q1 FY2021 | Mar 31, 2021 | $7.82 | – |
| Q4 FY2020 | Dec 31, 2020 | $9.55 | +311.6% |
| Q3 FY2020 | Sep 30, 2020 | $7.17 | +218.7% |
| Q2 FY2020 | Jun 30, 2020 | $2.37 | +22.8% |
| Q1 FY2020 | Mar 31, 2020 | -$3.27 | -275.8% |
| Q4 FY2019 | Dec 31, 2019 | $2.32 | +48.7% |
| Q3 FY2019 | Sep 30, 2019 | $2.25 | -27.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.93 | -15.0% |
| Q1 FY2019 | Mar 31, 2019 | $1.86 | +11.4% |
| Q4 FY2018 | Dec 31, 2018 | $1.56 | -76.5% |
| Q3 FY2018 | Sep 30, 2018 | $3.10 | +87.9% |
| Q2 FY2018 | Jun 30, 2018 | $2.27 | +27.5% |
| Q1 FY2018 | Mar 31, 2018 | $1.67 | -4.6% |
| Q4 FY2017 | Dec 31, 2017 | $6.63 | +278.9% |
| Q3 FY2017 | Sep 30, 2017 | $1.65 | – |
| Q2 FY2017 | Jun 30, 2017 | $1.78 | – |
| Q1 FY2017 | Mar 31, 2017 | $1.75 | – |
| Q4 FY2016 | Dec 31, 2016 | $1.75 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?